Minimally invasive concomitant aortic and mitral valve surgery: the “Miami Method”

Joseph Lamelas

Division of Cardiac Surgery, Mount Sinai Medical Center, Miami Beach, Florida, USA

Correspondence to: Joseph Lamelas, M.D. Chief of Cardiothoracic Surgery, Mount Sinai Medical Center, Mount Sinai Heart Institute 4300 Alton Road, Miami Beach, Florida 33140, USA. Email: jlamelasmd@aol.com.

Valve surgery via a median sternotomy has historically been the standard of care, but in the past decade various minimally invasive approaches have gained increasing acceptance. Most data available on minimally invasive valve surgery has generally involved single valve surgery. Therefore, robust data addressing surgical techniques in patients undergoing double valve surgery is lacking. For patients undergoing combined aortic and mitral valve surgery, a minimally invasive approach, performed via a right lateral thoracotomy (the “Miami Method”), is the preferred method at our institution. This method is safe and effective and leads to an enhanced recovery in our patients given the reduction in surgical trauma. The following perspective details our surgical approach, concepts and results for combined aortic and mitral valve surgery.

Keywords: Minimally invasive; valve surgery; aortic valve replacement; mitral valve surgery; double valve surgery

Submitted Jun 21, 2014. Accepted for publication Jul 17, 2014.

doi: 10.3978/j.issn.2225-319X.2014.08.17

View this article at: http://dx.doi.org/10.3978/j.issn.2225-319X.2014.08.17

Introduction

Minimally invasive valve surgery was first performed by Navia et al. in 1996, and by Cohn et al. in 1997 (1,2). When compared with a standard median sternotomy approach, the reported benefits of minimally invasive valve surgery include: reduced blood loss and pain, a lower morbidity, an enhanced recovery with shorter intensive care unit and hospital length of stay (2-8). Overall, the studies performed have involved single valve surgery in lower risk patients. At our institution, we have compared the outcomes of minimally invasive valve surgery with median sternotomy in high risk patients. We have demonstrated a reduced morbidity and lower resource utilization in those patients with chronic kidney disease (9), chronic obstructive pulmonary disease (10), those requiring re-operative mitral valve (11) and aortic valve (12) surgery. In addition, we observed a reduction in mortality in the elderly (13) and obese (14) patients. Because of these benefits, especially in high risk patients, it is reasonable to hypothesize that those needing concomitant aortic and mitral valve surgery would also benefit from a minimally invasive approach.

Technique for minimally invasive aortic and mitral valve surgery

At our institution, a femoral platform is utilized to establish cardiopulmonary bypass in the majority of cases. We do not perform preoperative screening of the aorta or peripheral vasculature. Careful attention is required during passage of the wire and subsequently the cannula. Intraoperative angiography is utilized when there are any concerns. We hypothesize that the increased stroke rate is attributed to the inadequate removal of air, aortic clamping of a diseased portion of the aorta or inadvertent removal of calcium or other debris that may have entered the heart at the time of surgery.

During our early experience, concomitant minimally invasive aortic and mitral valve surgery was performed via a 6 cm incision over the 4th intercostal space starting at the mid-clavicular line. The 4th interspace was entered and the lower cartilage was transected and re-attached at the completion of the operation. This access allowed excellent visibility of the aortic valve but limited the exposure of the mitral
valve as well as the ability to perform complex mitral valve repairs. With this approach, in order to obtain improved visibility of the mitral valve, an additional venous cannula was required in the superior vena cava and the long femoral venous cannula needed to be withdrawn into the inferior vena cava. This allowed increased mobility or buckling of the septum with the atrial lift system (Atrial Lift System, Miami Instruments, Miami, FL, USA) and thus improved exposure of the mitral valve. Despite this, exposure of the mitral valve was not comparable to that obtained via a minimally invasive mitral valve approach performed via a more lateral 4th to 5th intercostal space mini thoracotomy approach.

In an effort to perform more complex mitral valve repairs during concomitant aortic valve surgery, an alternative access was required. This involved placing the patient on the operating table with the right arm over the head and the right posterior chest wall elevated with a roll. An imaginary line is drawn from the middle of the entire sternum and extended laterally. A 6 cm incision is then performed lateral to the anterior axillary line. The intercostal space that coincides with the middle of the sternum is entered and transection of the rib is obviated. In our experience, patients with true double valve pathology will have an inferiorly displaced aorta allowing sufficient exposure of both valves via this access. The positioning and incision described was initially performed during our early experience with minimally invasive ascending aortic and hemi arch replacements with retrograde cerebral perfusion and circulatory arrest. It was observed during these procedures that exposure of both the aorta and the left atrium (Waterson’s groove) was excellent. Despite this, we now perform performing ascending aortic procedures via a 2nd or 3rd intercostal space mini-thoracotomy incision, similar to a minimally invasive aortic valve replacement approach because of the significant distance from the incision to the hemi arch.

Our myocardial protection strategy consists of one dose of a modified Del Nido solution (4:1 blood/crystalloid) delivered antegrade followed by subsequent retrograde doses if necessary. A retrograde cannula inserted via the right atrial appendage allows downward retraction of the appendage therefore providing additional exposure of the aorta.

In patients with myxomatous mitral valve disease involving the posterior leaflet, our preferred repair technique of choice is resection. With anterior leaflet pathology we “respect” the anterior leaflet and utilize artificial Goretex neochordae to re-establish competency of the mitral valve. In the majority of patients with rheumatic mitral disease, or radiation induced valvulopathy, we prefer to remodel the valve by performing anterior leaflet augmentation with a pericardial patch. Mitral valve replacement consists of either excision of the anterior leaflet with preservation of the posterior leaflet and chords, or preservation of both leaflets.

Replacement of the aortic valve is greatly facilitated by a complete circumferential transection of the ascending aorta, thus allowing for complete visualization of the aortic annulus. Closure of the aortotomy must be performed in a very meticulous two-layer fashion. There is a potential for bleeding from the posterior-medial suture line which can be very difficult to resolve. Butressing the suture line with a felt or pericardial strip may decrease the risk of bleeding. A small 1 cm segment of posterior aortic wall can be left intact if there is sufficient visualization of the aortic annulus. Another option is to perform a transverse aortotomy which can be extended deep into the non-coronary sinus in order to improve visibility of the non-coronary aspect of the annulus. Occasionally, a small pericardial patch is required to provide safe closure of the aorta at this level since direct approximation may be difficult.

Another interesting surgical option in extremely high-risk patients with poor left ventricular function and multiple co-morbidities, is to perform an aortic valve replacement and transaortic edge-to-edge repair of the mitral valve. In these patients, after removal of the aortic valve, the A2 and P2 segments of mitral valve are identified and an edge-to-edge repair is carried out with a 4-0 prolene suture placed in a mattress fashion and reinforced with felt plegets on the ventricular side of the mitral valve (15-18).

**Perspectives**

The annual incidence of double-valve surgery (concomitant aortic and mitral valve surgery) is approximately 3% to 14% of all valve surgery (19-21). The in-hospital mortality for these patients ranges from 9.6% to 15.6% (19-23), and is associated with diminished long-term survival (22,23). Most reports comparing minimally invasive surgery with median sternotomy have, to date, involved exclusively single valve surgery. Therefore, data concerning minimally invasive double valve surgery is limited (24).

An observational study by Karimov et al. (25), of 48 double valve procedures performed via a right antero-lateral mini-thoracotomy, demonstrated no postoperative mortality, nor conversions to median sternotomy; demonstrating that this approach is safe and feasible.

The operative technique that we utilize (the “Miami
Method”) for minimally invasive, minithoracotomy double valve surgery involving the aortic and mitral valve is demonstrated in a detailed video in this issue under the “Masters of Cardiothoracic Surgery” section.

Advantages

The benefits of minimally invasive surgery include decreased blood loss, transfusion requirements, and shorter intensive care unit and hospital length of stay. In addition, we have observed lower morbidity, and a reduction in mortality in the elderly and the obese patients. The time from discharge to full recovery is also significantly reduced.

The lateral minithoracotomy approach possibly offers the best exposure to both the aortic and mitral valves, even when compared to a median sternotomy. A sternal sparing approach for double valve disease eliminates the risk of sternal wound infection and mediastinitis. Elderly patients with physical impairments as well as patients with chronic obstructive pulmonary disease (COPD) can be offered more aggressive physical therapy as well as pulmonary toilet since the fear of sternal dehiscence is non existent. In addition, hybrid approaches can be offered with the potential of decreasing the mortality rates of combined coronary and valve disease.

Disadvantages

Minimally invasive double valve surgery requires longer aortic cross clamp and cardiopulmonary bypass times. The learning curve for this particular procedure is longer compared to isolated minimally invasive aortic or mitral valve surgery. The reported conversion rate to a median sternotomy is approximately 2.6% to 4.0% (26) and is usually attributed to inadequate exposure. We did not have any conversions in our cohort.

Caveats

Positioning the arm over the head facilitates the exposure in all patients, especially in female patients with large breasts and patients with an elevated right hemi diaphragm. Careful attention must be paid to specific landmarks to determine access into the chest. This approach allows for any type of complex mitral repair to be performed as well as aortic valve replacement and even concomitant replacement of the ascending aorta and hemi arch.

Clinical outcomes

At our institution, from November 2008 to April 2014, we performed 2,344 minimally invasive valve surgeries, of which, 169 consisted of primary aortic valve replacement with concomitant mitral valve replacement or mitral valve repair. This is the largest series of concomitant minithoracotomy aortic and mitral valve operations that we are aware of. The most common valvular pathology consisted of aortic stenosis with calcific degeneration of the mitral valve (32.4%). This was followed by aortic stenosis with functional mitral regurgitation (16.2%) and aortic insufficiency with functional mitral regurgitation (13.5%) (Table 1).

Of the 169 patients, 122 (72%) underwent aortic valve replacement with mitral valve repair, and 47 (28%) underwent replacement of both aortic and mitral valves. For the entire cohort, the mean age of these patients was 73±12 years, and there were 78 (46%) males and 91 (54%) females. The median aortic cross clamp and cardiopulmonary bypass times were 116 minutes [interquartile range (IQR), 91-138] and 145 minutes (IQR, 121-178), respectively. There were 4 (2.36%) patients that required re-operation for bleeding, and 2 (1.18%) suffered cerebrovascular accidents. The median hospital length of stay was 7 days (IQR, 6-12), and the 30-day mortality was 6 (3.55%) (Table 2). Of the entire cohort, 27 patients were performed as a hybrid procedure. A percutaneous intervention with a drug eluding stent was initially performed. Thereafter the minimally

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Type of valve pathology in patients undergoing combined aortic and mitral valve surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>Valve pathology</td>
<td>%</td>
</tr>
<tr>
<td>Aortic stenosis with calcific degeneration of mitral valve</td>
<td>32.4</td>
</tr>
<tr>
<td>Aortic stenosis with functional mitral regurgitation</td>
<td>16.2</td>
</tr>
<tr>
<td>Aortic insufficiency with functional mitral regurgitation</td>
<td>13.5</td>
</tr>
<tr>
<td>Aortic insufficiency and mitral regurgitation from previous endocarditis</td>
<td>13.5</td>
</tr>
<tr>
<td>Rheumatic aortic stenosis with mitral stenosis</td>
<td>11.0</td>
</tr>
<tr>
<td>Rheumatic aortic stenosis and mitral regurgitation</td>
<td>5.5</td>
</tr>
<tr>
<td>Aortic stenosis with myxomatous degeneration of mitral valve</td>
<td>5.5</td>
</tr>
<tr>
<td>Radiation induced aortic stenosis and mitral regurgitation</td>
<td>2.4</td>
</tr>
</tbody>
</table>
invasive double valve procedure was performed, with a median interval of 38 days between procedures. The use of percutaneous coronary intervention (PCI) followed by double valve surgery reduces the morbidity and mortality associated with the surgery. In addition, it allows a minimally invasive technique to be performed in patients with combined coronary and valvular disease.

### Conclusions

In summary, minimally invasive double valve surgery by means of a right mini-thoracotomy can be performed with low post-operative morbidity and mortality. In view of the evidence of safety and feasibility, a minimally invasive approach can be considered for patients undergoing double valve surgery.

### Acknowledgements

Dr. Chris Mihos and Dr. Andres Pineda for their contribution to this publication. Dr. Joseph Lamelas receives honoraria for lectures with Medtronic and St. Jude and is a partner in Miami Instruments.

All surgeries were performed by a single surgeon, Dr. Joseph Lamelas.

*Disclosure:* The author declares no conflict of interest.

### References
